Pilot Study of Narrowband UVB Phototherapy Three Times Weekly for 12 Weeks in Adults with Moderate to Severe Psoriasis

What this Trial Is About

Researchers are evaluating Narrowband Ultraviolet-B UVB phototherapy as a treatment for adults with moderate to severe chronic plaque-type psoriasis. This pilot study involves 30 patients and aims to assess the response to this phototherapy given three times a week over 12 weeks, followed by evaluations to see how well the treatment effects last through week 36. The study is conducted at a single center and sponsored by the Psoriasis Treatment Center of Central New Jersey. Participants will receive increasing doses of Narrowband UVB phototherapy three times weekly for 12 weeks. This open-label treatment phase is followed by periodic assessments every six weeks up to week 36 to monitor the maintenance of treatment response. The phototherapy is delivered using a device designed to emit ultraviolet B light, targeting the skin affected by psoriasis. During the study, patients will attend regular phototherapy sessions and follow-up visits. Researchers will evaluate changes in psoriasis severity using the Psoriasis Area Severity Index PASI score at 12 weeks as the primary outcome. Additional assessments include the Physicians Global Assessment, Body Surface Area affected, and a combined measure of these two at 12 weeks. Patients must be in good general health apart from psoriasis and able to comply with the treatment schedule and visits throughout the trial.

An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients